HD-OPM Archive
Topics › Lp(a)

Lipoprotein(a) explained: 80-90% genetic, stable for life, a risk factor beyond LDL

Gokhan Can · Oct 05, 2024 · ♥ 12 reactions · 8 comments · original Facebook post
Lp(a)LDL, ApoB & lipid panel
AI summary & key facts

Explainer on Lp(a): an LDL-like particle with apo(a) attached, 80-90% genetically determined, fully expressed by 1-2 years of age, and elevated in about 1 in 5 US individuals (1.4 billion globally). Levels above 50 mg/dL or 125 nmol/L raise ASCVD risk, possibly via impaired fibrinolysis and cholesterol deposition, and may occur with normal lipid panels.

Lipoprotein(a)

Lipoprotein(a) is a low-density lipoprotein (LDL) particle with an added apolipoprotein(a) [apo(a)] attached to the apolipoprotein B-100 (apoB100) component of the LDL particle via a disulfide bridge (Farzam et al, 2024). The structure of Lp(a) is highly heterogeneous due to many different apo(a) isoforms within the population.

An individual's Lp(a) level is 80-90% genetically determined in an autosomal codominant inheritance pattern. Lp(a) levels are fully expressed by 1-2 years of age, with adult-like levels achieved by approximately 5 years old. Outside of acute inflammatory states, a person's Lp(a) level remains relatively stable throughout their lifetime regardless of lifestyle factors (Scheel et al, 2019).

Elevated Lp(a) is estimated to affect more than 1.4 billion individuals globally and 1 in 5 individuals in the US, making it the most common genetic lipidemia (Demeter, 2023). Importantly, a person may have normal lipid levels and yet have elevated Lp(a).

Role in Cardiovascular Disease

High quality evidence from epidemiologic, Mendelian randomization, and genome-wide association studies supports a link between elevated Lp(a) levels and increased risk of various cardiovascular outcomes. Lp(a) levels >50 mg/dL or >125 nmol/L are associated with increased risk of ASCVD (Reyes-Soffer et al, 2022).

The exact pathophysiologic mechanisms are not entirely clear, but current theories propose a two-pronged contribution:

  1. Apo(a) has homology with plasminogen and has been shown in vitro to inhibit fibrinolysis. This could promote thrombosis at vulnerable arterial plaques or areas of turbulent flow.
  2. The LDL-like portion may promote intimal cholesterol deposition, though the cholesterol content even in very high Lp(a) levels is below traditional LDL cutoffs.
  3. Newer evidence suggests oxidized phospholipids co-localize with Lp(a) molecules and together may promote endothelial dysfunction, inflammation and calcification in vasculature (Tsimikas et al, 2005).

Lp(a) has been associated with increased risk of:

Some key findings from studies include:

Genome-wide association studies have found that high Lp(a) concentrations confer the highest risk of ASCVD and valvular aortic stenosis independent of other known causes and risk factors (Scheel et al, 2019).

Current Treatment Approaches

Despite the observed associations between elevated Lp(a) and ASCVD, there are currently no randomized controlled trials showing that targeted Lp(a) lowering improves clinical outcomes. As of 2023, there are no FDA-approved medications specifically for lowering Lp(a). However, some current therapies have shown Lp(a)-lowering effects:

PCSK9 Inhibitors:

Apheresis:

Notably, several common preventive strategies are ineffective for Lp(a):

Current guidelines recommend:

Novel Therapies in Development

Several promising therapies specifically targeting Lp(a) are in clinical trials:

0

PCNALp(a): Looking Beyond LDL to Assess ASCVD Risk - PCNAA risk calculator(opens in new tab) is an excellent tool in assessing potential risk for atherosclerotic cardiovascular disease (ASCVD), with a focus on age, sex, race, blood pressure, diabetes, tobacco use, and cholesterol—but clinicians should consider looking beyond LDL to assess ASCVD risk. One example is Lipoprotein(a), also known as…pcna.net

[i] Farzam K, Senthilkumaran S. Lipoprotein A. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Checking your browser - reCAPTCHA (ncbi.nlm.nih.gov)

[ii] Scheel P, Meyer J, Blumenthal RS, Martin SS. Lipoprotein(a) in Clinical Practice. July 2, 2019. *American College of Cardiology. *Lipoproteina in Clinical Practice (acc.org).

[viii] Kaiser Y, Singh SS, Zheng KH, et al. Lipoprotein(a) is robustly associated with aortic valve calcium. Heart. 2021. 107:1422–1428. The BMJ article (The BMJ)

Research cited

#ascvd#cardiovascular#statins#riskfactors#pcsk9#cardiology#genetics#cholesterol
← newer: Personal labs on tirzepatide/retatrutide and 5 mg rosuvastatolder: Prunes help maintain bone density in postmenopausal women, r →